beyondspring
forms
partnership
advisory
committee
comprised
industry
veterans
new
york
globe
newswire
beyondspring
company
beyondspring
nasdaq
bysi
global
biopharmaceutical
company
focused
development
innovative
neutropenia
therapies
announced
today
formed
partnership
advisory
committee
comprised
former
pharmaceutical
veterans
industry
leaders
committee
tasked
supporting
beyondspring
business
development
activities
related
lead
asset
plinabulin
pipeline
assets
mukul
agarwal
former
vice
president
corporate
development
forty
seven
daniel
zabrowski
former
global
head
pharma
partnering
roche
current
beyondspring
board
member
appointed
initial
members
committee
company
expects
name
additional
members
time
beyondspring
nears
submission
plinabulin
new
drug
application
nda
commercialization
access
industry
veterans
bring
bear
track
records
striking
successful
partnerships
utmost
importance
said
huang
especially
grateful
agarwal
join
committee
instrumental
gilead
acquisition
forty
seven
rely
guidance
agarwal
zabrowski
help
beyondspring
develop
meaningful
partnerships
plinabulin
pipeline
assets
greatly
benefit
patients
deliver
value
agarwal
years
experience
working
pharmaceutical
small
biotech
companies
currently
serves
recode
therapeutics
chief
business
officer
previously
vice
president
corporate
development
forty
seven
gilead
acquired
billion
march
prior
forty
seven
agarwal
served
vice
president
corporate
development
strategy
revance
therapeutics
senior
director
business
development
licensing
anacor
pharmaceuticals
pfizer
acquired
billion
also
director
global
business
development
licensing
forest
pharmaceuticals
acquired
allergan
abbvie
served
roles
medimmune
astrazeneca
glaxosmithkline
zabrowski
previously
worked
years
roche
number
key
global
leadership
positions
including
global
head
regulatory
affairs
global
head
development
operations
global
head
pharma
partnering
tenure
business
development
zabrowski
teams
executed
acquisition
partnership
deals
currently
serves
venture
partner
decheng
capital
beyondspring
reached
important
inflection
point
company
added
agarwal
recently
receiving
breakthrough
therapy
designation
beyondspring
expected
file
nda
plinabulin
hopeful
result
rapid
approval
allows
us
help
many
patients
beyondspring
headquartered
new
york
beyondspring
global
biopharmaceutical
company
focused
development
innovative
neutropenia
therapies
improve
clinical
outcomes
beyondspring
lead
immune
asset
plinabulin
potent
cell
inducer
currently
phase
clinical
trials
two
severely
unmet
medical
needs
indications
one
prevention
neutropenia
cin
frequent
cause
chemotherapy
regimen
dose
decrease
delay
downgrade
discontinuation
lead
suboptimal
clinical
outcomes
plinabulin
recently
received
breakthrough
therapy
designation
fda
china
nmpa
cin
indication
indication
cell
lung
cancer
treatment
egfr
patients
pipeline
drug
plinabulin
various
combination
studies
boost
antibody
effects
addition
plinabulin
beyondspring
extensive
pipeline
includes
three
assets
drug
discovery
platform
dubbed
molecular
glue
uses
protein
degradation
pathway
cautionary
note
regarding
statements
press
release
includes
statements
historical
facts
words
expect
anticipate
plan
believe
design
may
future
estimate
predict
objective
goal
variations
thereof
variations
words
similar
expressions
intended
identify
statements
statements
based
beyondspring
current
knowledge
present
beliefs
expectations
regarding
possible
future
events
subject
risks
uncertainties
assumptions
actual
results
timing
events
could
differ
materially
anticipated
statements
result
several
factors
including
limited
difficulties
raising
anticipated
amount
needed
finance
company
future
operations
terms
acceptable
company
unexpected
results
clinical
trials
delays
denial
regulatory
approval
process
results
meet
expectations
regarding
potential
safety
ultimate
efficacy
clinical
utility
product
candidates
increased
competition
market
risks
described
beyondspring
recent
form
file
securities
exchange
commission
statements
made
herein
speak
date
release
beyondspring
undertakes
obligation
update
publicly
statements
reflect
subsequent
events
circumstances
except
otherwise
required
law
media
contacts
caitlin
kasunich
raquel
cona
kcsa
strategic
communications
ckasunich
rcona
